Source | hr.economictimes.indiatimes.com | Teena Thacker
New Delhi: Drug marker Macleods Pharmaceuticals has decided to put its staff on prophylaxis treatment of hydroxychlroquine (HCQ), even as a debate rages over its efficacy in treating Covid-19 and whether it should be given to non-health workers.
In a circular issued on Tuesday, Macleods’ executive president, medical services, asked employees to send their names to the HR department so that prophylactic treatment of HCQ can be initiated.
The company cited encouraging results published in the Indian Journal of Medical Research on use of HCQ and said it “would like to give prophylaxis treatment to all our staff”. It recommended taking 400 mg on day 1, then 400 mg once every week for seven weeks. “We will be giving this dose through our team of medical doctor. They will examine you, take medical history and explain you the dosage schedule and required precautions,” said the circular.